US · EDAP
Edap Tms S.a.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Vaulx-en-Velin 69120
- Website
- edap-tms.com
Price · as of 2024-12-31
$3.47
Market cap 163.4M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $35.70 | +928.82% |
| Intrinsic Value(DCF) | $1.03 | -70.32% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $3.99 | $28.61 | $0.44 | $0.00 | $0.00 |
| 2011 | $2.10 | $116.17 | $0.08 | $0.10 | $0.00 |
| 2012 | $4.52 | $98.63 | $0.00 | $0.00 | $0.00 |
| 2013 | $3.34 | $77.08 | $0.00 | $0.00 | $0.00 |
| 2014 | $3.44 | $54.79 | $0.20 | $0.50 | $0.00 |
| 2015 | $4.29 | $176.81 | $0.54 | $0.20 | $0.00 |
| 2016 | $2.75 | $60.22 | $5.09 | $1.70 | $2.90 |
| 2017 | $2.22 | $252.03 | $0.50 | $0.80 | $0.00 |
| 2018 | $2.90 | $71.82 | $0.47 | $0.80 | $0.00 |
| 2019 | $3.54 | $70.29 | $0.93 | $1.30 | $1.30 |
| 2020 | $8.11 | $49.43 | $0.81 | $0.60 | $0.00 |
| 2021 | $7.24 | $35.25 | $1.35 | $1.90 | $0.30 |
| 2022 | $11.95 | $118.70 | $1.54 | $1.90 | $0.00 |
| 2023 | $7.50 | $32.74 | $0.42 | $0.00 | $0.00 |
| 2024 | $2.54 | $30.49 | $0.05 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Edap Tms S.a.'s (EDAP) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $35.70
- Current price
- $3.47
- AI upside
- +928.82%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.03
-70.32% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| EDAP | Edap Tms S.a. | $3.47 | 163.4M | +779% | -70% | — | — | -4.26 | 1.98 | 1.26 | -4.08 | — | 2.16 | 41.42% | -32.03% | -29.66% | -38.88% | -87.65% | -21.42% | 0.34 | -87.01 | 1.85 | 1.33 | 1.00 | -1053.00% | 611.00% | -679.00% | -21.85% | -0.36 | -75.49% | 0.00% | 0.00% | 0.00% | -3.17 | -3.68 | 1.01 | 0.14 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| FBIO | Fortress Biotech, Inc. | $3.42 | 106.15M | +410% | -82% | — | +1,342% | -0.26 | 1.41 | 0.55 | -0.49 | — | -3.51 | 63.80% | -191.38% | -79.75% | -533.80% | -308.14% | -77.53% | 3.34 | -11.12 | 1.27 | 0.95 | -0.18 | -6824.00% | -3176.00% | -3017.00% | -297.40% | -1.12 | -265.74% | 14.72% | -3.90% | 14.72% | -0.46 | -0.53 | 0.88 | -9.03 |
| HYPR | Hyperfine, Inc. | $1.07 | 81.53M | +2,340% | -64% | — | — | -1.74 | 1.45 | 5.51 | -0.80 | — | 1.45 | 45.70% | -335.33% | -315.90% | -61.03% | -410.39% | -53.19% | 0.01 | — | 6.15 | 5.26 | 0.89 | -968.00% | 1684.00% | -813.00% | -55.17% | -4.44 | -371.71% | 0.00% | 0.00% | 0.00% | -0.78 | -0.86 | 2.61 | -3.97 |
| INCR | InterCure Ltd. | $0.83 | 45.39M | +740% | -23% | — | +1,093% | -3.53 | 0.65 | 1.08 | -7.60 | -80.10 | 1.49 | 12.66% | -28.14% | -28.38% | -17.09% | -10.38% | -9.40% | 0.53 | -3.26 | 1.73 | 1.14 | -2.59 | 441.00% | -3282.00% | 2676.00% | -27.72% | -0.30 | -13.21% | 0.00% | 0.00% | 0.00% | -5.80 | -5.47 | 1.63 | 0.20 |
| LUNG | Pulmonx Corporation | $1.58 | 65.17M | +1,684% | +90% | — | — | -5.19 | 3.41 | 3.49 | -4.87 | — | 3.50 | 74.00% | -68.87% | -67.30% | -55.25% | -138.32% | -33.11% | 0.66 | -16.45 | 5.58 | 4.72 | 0.28 | -1000.00% | 2201.00% | -1414.00% | -11.27% | -1.29 | -79.07% | 0.00% | 0.00% | 0.00% | -4.29 | -7.50 | 2.95 | -1.57 |
| MDAI | Spectral AI, Inc. | $1.40 | 42.96M | +2,693% | -59% | — | — | -1.69 | -3.56 | 0.87 | -2.21 | — | -3.56 | 44.87% | -22.25% | -51.77% | 341.85% | 101.83% | -134.42% | -0.65 | -2.22 | 0.57 | 0.43 | 0.04 | -4257.00% | 6383.00% | -3052.00% | -35.62% | -0.52 | 142.31% | 0.00% | 0.00% | 0.00% | -3.85 | -2.76 | 0.86 | -4.86 |
| NSPR | InspireMD, Inc. | $1.78 | 75.42M | +1,242% | -35% | — | — | -3.72 | 3.30 | 16.99 | -2.61 | — | 3.30 | 21.49% | -478.00% | -456.63% | -84.68% | -1143.45% | -67.77% | 0.06 | — | 5.28 | 4.80 | 0.50 | -732.00% | 1296.00% | 3887.00% | -19.54% | -2.85 | -794.20% | 0.00% | 0.00% | 7.17% | -2.59 | -3.73 | 12.38 | -2.29 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| VANI | Vivani Medical, Inc. | $1.23 | 72.67M | — | — | — | — | -2.53 | 3.37 | — | -2.49 | — | 3.37 | 0.00% | — | — | -122.42% | -125.35% | -53.77% | 1.10 | — | 3.41 | 3.11 | -0.04 | -1400.00% | — | -1319.00% | -35.94% | -3.47 | -108.41% | 0.00% | 0.00% | 0.00% | -2.45 | -2.83 | — | -4.16 |
About Edap Tms S.a.
EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications. This segment also offers Ablatherm, an ultrasound guided robotic HIFU device for the treatment of organ-confined prostate cancer; Ablatherm Fusion that incorporates the company's proprietary fusion software, which merges MRI and ultrasound images; and the Focal One, a HIFU robotic device dedicated to the focal therapy of prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. The ESWL division manufactures, markets, and services lithotripter for the treatment of urinary tract stones by means of ESWL technology; and offers Sonolith i-move, an extracorporeal shockwave lithotripter to small and mid-size hospitals, as well as sells disposable parts for lithotripters and electrodes. The Distribution division markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales organization, and service platform, as well as through third-party distributors and agents. Its customers include hospitals, urology clinics, and research institutions. The company was incorporated in 1979 and is headquartered in Lyon, France.
- CEO
- Ryan Rhodes
- Employees
- 310
- Beta
- -0.18
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.03 ÷ $3.47) − 1 = -70.32% (DCF, example).